Winners of the national Hospital of the Year award

Thomas Drive
Liverpool
L14 3PE

Switchboard: 0151 600 1616
www.lhch.nhs.uk

Study number: 2016AZLIDN001
IRAS: 206907

Patient Information Sheet

Study title: AZTEC-CF

This study has the official study title: Aztreonam for inhalation solution (AZLI) for the treatment of exacerbations of CF. An open-label randomised cross-over pilot study of AZLI plus intravenous colistin® versus standard dual intravenous therapy.

Study doctor:
Dr Freddy Frost
Cystic Fibrosis Fellow
Research Unit
Liverpool Heart and Chest Hospital
Freddy.Frost@lhch.nhs.uk

Research nurse:
Sharron Burnett
Research Unit
Liverpool Heart & Chest Hospital
Thomas Drive, Liverpool, L14 3PE
Sharon.burnett@lhch.nhs.uk
01512821616

Date 14/12/16 Version 2.4

INVITATION

Dear Participant:

You are being invited to take part in a research study for participants with Cystic Fibrosis. Before you decide, it is important for you to understand why the research is being carried out and what it will involve. This information leaflet will give you the information you will need to understand why this study is being done and why you are being invited to participate. It will also describe what you need to do to participate and possible risks, inconveniences, and discomforts that you may have while participating. If you decide to participate, you will be asked to sign a consent form and it will be a record of your agreement to participate. You will be given a signed and dated copy of the consent form.

It is important that you read and understand this leaflet. We encourage you to take some time to think this over and to discuss it with your family, friends, and doctor. We also encourage you to ask questions at any time.

1. Summary - Description and relevance of this study to you

What is the purpose of the study?

Repeated courses of antibiotics via a drip (also known as intravenous or IV antibiotics) can cause long-term side effects including deafness and chronic kidney disease. It is therefore important to explore newer approaches for treating chest infections in CF. Nebulised antibiotics provide an opportunity to deliver antibiotics straight to the lungs with significantly less of the drug being absorbed into the blood stream. This means that potential side effects and long-term damage to other organs are minimised. Furthermore nebulised antibiotics are generally well tolerated, less invasive and require less time to administer. AZTEC-CF aims to evaluate whether inhaled antibiotic treatment is beneficial in the treatment of acute chest infections

Why have I been chosen?

You are being asked to take part as you have CF, with lung function of between 25% - 75% and you are known to grow Psa in your sputum.

What is the study drug being tested?

AZTEC-CF will use Cayston® to treat chest infections that require admission to hospital and compare it against IV antibiotics. Cayston® is currently used to treat long-term pseudomonas infection and has been shown to be safe and effective at improving lung function and preventing admissions to hospital.

Do I have to take part?

No. Participation is voluntary. It is up to you to decide whether you take part. If you decide not to participate in the study, you will continue your routine treatment.

What can I expect if I want to take part?

If you wish to participate, you will be asked to sign a consent form and then you will start in the study the next time you require an admission for IVs. You are free to withdraw from the study at any time and without giving a reason. Withdrawal will not affect the standard medical care you receive in any way.

What will happen during the study?

During the study, you will receive two treatments over the course of your next two admissions with a chest infection. The two treatments are:

1/ Cayston® plus IV Colistin ®

2/ Two IV antibiotics (Colistin® plus one other)

Both treatments will last 14 days, the standard accepted treatment length in the UK.

The study is a randomized crossover study, which means that the first study treatment you will receive will be selected randomly, like tossing a coin. You will then complete the first course of treatment. Upon your next admission you will receive the treatment you did not have on the first admission. You will remain on your other routine CF treatments and can continue their standard therapies during the course of the study. Table 1 at the end of this sheet shows which tests you will have and when.

Information and data that will be collected during the study

- Medical history:
- Demographic and other characteristics:
- Complete physical examination:
- Cystic Fibrosis Questionnaire Revised (CFQ-R): A questionnaire that takes five minutes to complete.Only people directly involved in this research study will have access to the collected information.
- Any non-identifiable information and data collected during this study may (with your consent) be shared along with the results of the study with other researchers. Other researchers will not be able to identify you in any way.

Measurements that will be performed during the study

NB: All of these measurements are also performed as part of routine care

- Height
- Weight
- Body temperature
- Blood pressure and pulse
- Lung function tests
- Oxygen saturation (pulse oximetry)
- Blood tests

2. Information on risks and benefits

What are the side effects or risks of taking part?

The main risks of taking part are side-effects associated with Cayston® which can include cough, nasal congestion, wheezing and in some cases chest discomfort. You will receive a test dose of Cayston® prior to starting the trial to ensure you don't suffer any significant side-effects. There is a risk that Cayston® may not work as well as IV antibiotics, if it is apparent that continuing Cayston® is not in your best interests you will be switched back to two IV antibiotics.

What are the possible benefits of taking part?

There is no guarantee or certainty you will have any benefit from the study drug, however it is expected that while you are receiving Cayston® you will be subjected to less intravenous medication and spend a shorter amount of time per day completing your antibiotic regimen.

What happens if new information is found during the study?

If any new information becomes available during the study that may affect your decision to continue to take part, you will be informed. You will be asked to sign a form indicating your decision of whether to continue or not.

What if something goes wrong or I have problems while I am in the study?

Complaints: If you wish to complain formally, you can do this through the NHS Complaints Procedure, (details can be obtained from PALS at LHCH) or you can find further information

on ethics in research on the National Research Ethics Service website (www.nres.npsa.nhs.uk).

Harm: If you are harmed and this is due to someone's negligence then you may have grounds for legal action or compensation against Liverpool Heart & Chest Hospital (in respect of any harm arising out of the participation in the Clinical Trial) or the NHS (in respect of any harm which has resulted from the clinical procedure being undertaken).

What about pregnancy?

Cayston(R) is not thought to be harmful during pregnancy however, at present there is not enough data to be completely sure and hence if you are pregnant you will not be allowed to enter the trial. To be safe, it is important that you and your partner use highly effective contraception* for the 14 days you receive each set of antibiotics in the trial and for 24 hours after completing the trial medication. If you or your partner fall pregnant during the trial you should let a team member know as soon as possible.

*High effective contraception includes:

- combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
    - o oral
    - o intravaginal
    - o transdermal
- progestogen-only hormonal contraception associated with inhibition of ovulation
    - o oral
    - o injectable
    - o implantable
- intrauterine device (IUD)
- intrauterine hormone-releasing system (IUS)
- bilateral tubal occlusion
- vasectomised partner
- sexual abstinence

Other important information

Who funds the study?

Gilead Sciences (USA), the manufacturer or Cayston®, has funded the study. Gilead Sciences will not be involved in the running of the study, which will be the responsibility of the team at LHCH.

Will the study cost me anything or do I receive payment or compensation?

There will be no extra costs to you for your drug or for your tests, examinations or medical care required as part of this study. You will not be paid for taking part in this study and there is no provision of payments for expenses.

How will my data and biological material be handled and used?

Data: During your participation in the study, personal data, such as information on your medical condition, will be collected. Any paper records will be kept locked in a secure area of the Research Unit at LHCH. Electronic data will be stored in a password protected area of the trusts computer system. This personal data will be secured against unauthorized access and kept confidential. No

With your consent, your General Practitioner (GP) will be informed about your participation in the study. We would do this to ensure that we and your GP can best manage your overall healthcare.

Biological Material: The blood samples collected will be analysed at LHCH. Sputum samples will be transported to the University of Liverpool and analysed there. Samples will be labeled with your specific trial ID so that only members of the research team at LHCH can identify you from them.

What will happen to the overall results of the study?

Results will be published on clinicaltrials.gov, the LHCH website and also at various CF conferences and journals.

What will happen if I do not wish to carry on with the study?

If you do withdraw from the study your standard of care would not be affected. As part of your ongoing CF care you will still be asked to attend routine follow up at LHCH but these appointments will not be part of the study.

What will happen at the end of the study?

At the end of the study, your normal standard of care will continue as before. Taking part in this study will not affectyour eligibility to receive Cayston® in the future. Some samples from this study may be stored for use in future research.

Who can I contact for further information?

If you would like to take part in this study or have further questions, please contact your usual doctor, the study doctor, or the research nurses (see front page)

Thank you for taking the time to read this information

Table 1: What will happen at each visit? *=part of routine care

Initial clinic		• Consent • Spirometry* • Cayston® test dose (this may occur at a convenient time after initial clinic)
Admission 1	**Day 1**	• Start first treatment – 14 day course of IV Colistin PLUS either Cayston® or another IV antibiotic* • Blood Tests* • Sputum Sample* • CFQ-R questionnaire
	Day 7	• Spirometry* • Blood tests
	Day 14	• Complete first treatment • Blood tests • Spirometry* • Sputum sample • CFQ-R questionnaire
Clinic: Two weeks post-discharge		• Spirometry*
Admission 2	**Day 1**	• Start second treatment – 14 day course of IV Colistin PLUS either Cayston® or another IV antibiotic* • Blood Tests* • Sputum Sample* • CFQ-R questionnaire
	Day 7	• Spirometry* • Blood tests
	Day 14	• Complete first treatment • Blood tests • Spirometry • Sputum sample • CFQ-R questionnaire
Clinic: Two weeks post-discharge		• Spirometry*